AZTR Quote, Financials, Valuation and Earnings

CEL-SCI Corp. has a net margin of 23.36% compared to Azitra, Inc.'s net margin of --. Azitra, Inc.'s return on equity of -245.12% beat CEL-SCI Corp.'s return on equity of -266.61%.

Azitra, Inc. has a consensus price target of $2.70, signalling upside risk potential of 644.62%. On the other hand CEL-SCI Corp. has an analysts' consensus of $42.50 which suggests that it could grow by 558.92%. Given that Azitra, Inc. has higher upside potential than CEL-SCI Corp., analysts believe Azitra, Inc. is more attractive than CEL-SCI Corp..

Azitra, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison CEL-SCI Corp. has a beta of 0.487, suggesting its less volatile than the S&P 500 by 51.259%.

Azitra, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. CEL-SCI Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Azitra, Inc. pays -- of its earnings as a dividend. CEL-SCI Corp. pays out -- of its earnings as a dividend.

Azitra, Inc. quarterly revenues are --, which are smaller than CEL-SCI Corp. quarterly revenues of --. Azitra, Inc.'s net income of -$2.8M is higher than CEL-SCI Corp.'s net income of -$5.7M. Notably, Azitra, Inc.'s price-to-earnings ratio is -- while CEL-SCI Corp.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Azitra, Inc. is 6.94x versus -- for CEL-SCI Corp.. Usually stocks with elevated PS ratios are considered overvalued.

Olema Pharmaceuticals, Inc. has a net margin of 23.36% compared to Azitra, Inc.'s net margin of --. Azitra, Inc.'s return on equity of -245.12% beat Olema Pharmaceuticals, Inc.'s return on equity of -45.61%.

Azitra, Inc. has a consensus price target of $2.70, signalling upside risk potential of 644.62%. On the other hand Olema Pharmaceuticals, Inc. has an analysts' consensus of $36.50 which suggests that it could grow by 34.14%. Given that Azitra, Inc. has higher upside potential than Olema Pharmaceuticals, Inc., analysts believe Azitra, Inc. is more attractive than Olema Pharmaceuticals, Inc..

Azitra, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Olema Pharmaceuticals, Inc. has a beta of 1.870, suggesting its more volatile than the S&P 500 by 86.967%.

Azitra, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Olema Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Azitra, Inc. pays -- of its earnings as a dividend. Olema Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Azitra, Inc. quarterly revenues are --, which are smaller than Olema Pharmaceuticals, Inc. quarterly revenues of --. Azitra, Inc.'s net income of -$2.8M is higher than Olema Pharmaceuticals, Inc.'s net income of -$42.2M. Notably, Azitra, Inc.'s price-to-earnings ratio is -- while Olema Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Azitra, Inc. is 6.94x versus -- for Olema Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Rapt Therapeutics, Inc. has a net margin of 23.36% compared to Azitra, Inc.'s net margin of --. Azitra, Inc.'s return on equity of -245.12% beat Rapt Therapeutics, Inc.'s return on equity of -67.79%.

Azitra, Inc. has a consensus price target of $2.70, signalling upside risk potential of 644.62%. On the other hand Rapt Therapeutics, Inc. has an analysts' consensus of $65.00 which suggests that it could grow by 88.6%. Given that Azitra, Inc. has higher upside potential than Rapt Therapeutics, Inc., analysts believe Azitra, Inc. is more attractive than Rapt Therapeutics, Inc..

Azitra, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Rapt Therapeutics, Inc. has a beta of 0.428, suggesting its less volatile than the S&P 500 by 57.168%.

Azitra, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Rapt Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Azitra, Inc. pays -- of its earnings as a dividend. Rapt Therapeutics, Inc. pays out -- of its earnings as a dividend.

Azitra, Inc. quarterly revenues are --, which are smaller than Rapt Therapeutics, Inc. quarterly revenues of --. Azitra, Inc.'s net income of -$2.8M is higher than Rapt Therapeutics, Inc.'s net income of -$17.6M. Notably, Azitra, Inc.'s price-to-earnings ratio is -- while Rapt Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Azitra, Inc. is 6.94x versus 54.16x for Rapt Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Replimune Group, Inc. has a net margin of 23.36% compared to Azitra, Inc.'s net margin of --. Azitra, Inc.'s return on equity of -245.12% beat Replimune Group, Inc.'s return on equity of -82.53%.

Azitra, Inc. has a consensus price target of $2.70, signalling upside risk potential of 644.62%. On the other hand Replimune Group, Inc. has an analysts' consensus of $12.57 which suggests that it could grow by 18.49%. Given that Azitra, Inc. has higher upside potential than Replimune Group, Inc., analysts believe Azitra, Inc. is more attractive than Replimune Group, Inc..

Azitra, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Replimune Group, Inc. has a beta of 0.659, suggesting its less volatile than the S&P 500 by 34.125%.

Azitra, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Replimune Group, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Azitra, Inc. pays -- of its earnings as a dividend. Replimune Group, Inc. pays out -- of its earnings as a dividend.

Azitra, Inc. quarterly revenues are --, which are smaller than Replimune Group, Inc. quarterly revenues of --. Azitra, Inc.'s net income of -$2.8M is higher than Replimune Group, Inc.'s net income of -$83.1M. Notably, Azitra, Inc.'s price-to-earnings ratio is -- while Replimune Group, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Azitra, Inc. is 6.94x versus -- for Replimune Group, Inc.. Usually stocks with elevated PS ratios are considered overvalued.